Difference between revisions of "Moxetumomab pasudotox (Lumoxiti)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
m |
||
Line 1: | Line 1: | ||
− | =Mechanism of action= | + | ==Mechanism of action== |
A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) | A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38) | ||
− | = | + | ==Diseases for which it is used== |
− | ==[[Hairy cell leukemia] | + | *[[Hairy cell leukemia]] |
− | |||
− | |||
− | =Also known as= | + | ==History of changes in FDA indication== |
− | *'''Code | + | *9/13/2018: Initial FDA approval "for adult patients with relapsed or refractory [[Hairy cell leukemia|hairy cell leukemia (HCL)]] who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA)." |
+ | |||
+ | ==Also known as== | ||
+ | *'''Code names:''' CAT-8015, HA22 | ||
+ | *'''Brand name:''' Lumoxiti | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
Line 19: | Line 21: | ||
[[Category:Hairy cell leukemia medications]] | [[Category:Hairy cell leukemia medications]] | ||
− | [[Category: | + | [[Category:FDA approved in 2018]] |
Revision as of 19:12, 13 September 2018
Mechanism of action
A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38)
Diseases for which it is used
History of changes in FDA indication
- 9/13/2018: Initial FDA approval "for adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA)."
Also known as
- Code names: CAT-8015, HA22
- Brand name: Lumoxiti